Experience using low doses of calcineurin inhibitors in the treatment of refractory lupus nephritis
PDF (Español)
PDF

Keywords

Lupus nephritis
cyclosporine
tacrolimus.

How to Cite

1.
Restrepo Valencia CA, Vélez Álvarez C. Experience using low doses of calcineurin inhibitors in the treatment of refractory lupus nephritis. Rev. Colomb. Nefrol. [Internet]. 2014 Jul. 1 [cited 2024 Jul. 18];1(2):80-91. Available from: https://revistanefrologia.org/index.php/rcn/article/view/179

Abstract

Objective. To evaluate the effectiveness of calcineurin ciclosporin and tacrolimus inhibitors to induce remission in patients with refractory lupus nephritis. Patients, materials and methods.

Patients with lupus nephritis class IV-G who despite receiving therapy with high doses of steroid and with a cytostatic (cyclophosphamide or mycophenolate) for 3 months had not been able to induce some kind of remission.The exclusion criteria were creatinine levels greater than 3 mg / dl, pregnancy, previous history of exposure to calcineurin inhibitors, cancer, active infections, uncontrolled hypertension, and negligence with medication intake. The recommended dose of cyclosporine was 3 mg / kg / day and tacrolimus 0.1 mg / kg / day, in joint with prednisone 0.3 mg / kg / day, cyclophosphamide 1 mg / kg / day or mycophenolate mofetil 1 gram every 12 hours. The cyclophosphamide was administered only during 6 months, after which it was changed to azathioprine at doses of 1 mg / kg / day. Still, mycophenolate was continued at the same dose. All patients completed a minimum period of 12 months follow-up, it was considered that patients achieved partial remission when proteinuria decreased by 50% of the baseline value or its value decreased to less than 1 gram in 24 hours, decrease of leukocytes count and red blood cells in urine of 50%, and creatinine values were stable. A complete remission was considered when there was a reduction in proteinuria in a value less than 300 mg per 24 hours, urinary sediment with less than 3 red blood cells, less than 5 leukocyte for each high power microscopic field, and a creatinine value reduction by 50% or reaching a normal value.


Results. Twelve patients met the inclusion criteria and initiated the calcineurin inhibitor protocol. Two presented accelerated deterioration in their function and required chronic dialysis therapy. Ten patients with active treatment completed 12 months of follow-up, of which 4 (40%) had partial remission (PR), 5 (50%) complete remission (RC). One patient had no significant modification to his baseline values. The following findings were made for all the patients with any significant degree of remission: their creatinine
levels were reduced significantly from an average value of 1,34 +/-0,7 mg/dl to an average of 0,96 +/- 0,3 mg/dl and 0,97 +/- 0,24 mg/dl for measurements taken 6 and 12 months respectively after the start of the treatment (p<0,05). The protein levels in the urine in a timeframe of 24 hours changed from a baseline value of 2865 +/- 2586.7 milligrams to 824 +/- 981.9 milligrams at 6 months, and 488 +/- 697.7 milligrams at 12 months (p <0.05). On average, in both PR and CR patients, the C3 levels raised unlike the values for antinuclear antibodies that were diminished. No patients died, nor were there significant side effects triggered by medications. No patient presented relapses during the follow-up time.

Conclusion. The calcineurin inhibitors at low doses are an important alternative to induce partial or complete remission in patients with refractory lupus nephritis compared to classic steroid and cytostatic treatment. It is required to do a long-term follow-up to establish its safety profile at low doses and relapse rate after suspension.

https://doi.org/10.22265/acnef.1.2.179
PDF (Español)
PDF

References

1. Cameron J S. Lupus Nephritis. J Am Soc Nephrol 10:413-424.

2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO, Chwalinska-Sadowska H, de Ramón E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.

3. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 Mar 6;314(10):614-619.

4. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741- 45.

5. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549-557.

6. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:968-975.

7. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997;51:1188-1195.

8. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544-550.

9. Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis. 1994;24:159-171.

10. Barr RG, Seliger S, Appel GB, Zuniga R, D’Agati V, Salmon J, Radhakrishnan J.Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039-2046.

11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.

12. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M, International Society of Nephrology Working Group on the Classification of Lupus Nephritis, Renal Pathology Society Working Group on the Classification of Lupus Nephritis. Kidney Int. 2004;65:521-530.

13. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramón Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61.

14. Nefropatia lúpica. Serna Flórez J, Restrepo Valencia C A en Nefrología Básica 2. Restrepo CA, Buitrago CA, Torres J, Serna J. Editorial La Patria, 2012, pág. 113-120, Manizales.

15. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012;Suppl 2:143-153, Chapter 12: Lupus nephritis.

16. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care Res Volume 2012;64:797-808.

17. The Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendation for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-1782.

18. Griffiths B, Emery P. The treatment of lupus with cyclosporin A. Lupus. 2001;10(3):165-170.

19. Gordon C, Matthews N, Schlesinger B C, Akbar A N, Bacon P A, Emery P, Salmon M. Active systemic lupus erythematosus is associated with the recruitment of naive/resting t cells. Rheumatology 1996;35:226-230.

20. Favre H, Miescher P A, Huang Y P et al. Cyclosporin in the treatment of lupus nephritis. Am J Nephrol 1989;9(suppl):57-60.

21. Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, Merta M, Rysava R, Tesar V. Treatment of lupus nephritis with cyclosporine - an outcome analysis. Kidney Blood Press Res. 2007;30(2):124-128.

22. Tam L S, Li E K, Leung C B, Wong K C, Lai F M M, Wang A, Szeto C C, Lui S F. Long term treatment of lupus nephritis with cyclosporin A. Q J Med 1998;91:573-580.

23. Ferrario L, Bellone M, Bozzolo E, Baldissera E, Sabbadini M G. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology 2000;39:218-220.

24. Manger K, Kalden J R, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. British J Rheumatology 1996;35:669-675.

25. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheumatism 1994;37:551-558.

26. Caccavo D, Laganà B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, Bonomo L. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheumatism 1997;40:27-35.

27. Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 2010;19:162-169.

28. Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, Amano K, Takeuchi T. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol 2007;17:92-97.

29. Baca V, Catalán T, Villasís-Keever M, Ramón G, Morales AM, Rodríguez-Leyva F. Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus 2006;15:490-495.

30. Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clinical Nephrology 2004;62:49-53.

31. Duddridge M, Powell RJ. Treatment of severe and difficult cases f systemic lupus erythematosus with tacrolimus. Areport of three cases. Ann Rheum Dis 1997;56:690-692.

32. Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, Oryoji K, Shimoda T, Niiro H, Tada Y, Yano T, Nonaka T, Oishi R, Akashi K, Horiuchi T. Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria. Clinical Experimental Rheumatology 2010;28:6-12.

33. Fei Y, Wu Q, Zhang W, Chen H, Hou Y, Xu D, Li M, Zhang X, Zhao Y, Zeng X, Zhang F. Low dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol 2013;31:62-68.

34. Gordon S, Denunzio T, Uy A. Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria. Hawaii J Med Public Health 2013;72:18-23.

35. Wang S, Li X, Qu L, Wang R, Chen Y, Li Q, He X, Zhang X, Wang H, Wu J, Xu Y, Chen J. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 2012;21:1025-1035.

36. Deng J, Huo D, Wu Q, Yang Z, Liao Y. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med 2012;227:281-288.

37. Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F, Liao Y, Yang Z, Zhang J, Chen J, Lou T, Fu J, Kong Y, Liu Z, Li Z, Yu X. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012;21:944-952.
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.